Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death

Cell Death and Disease

Volumn 6, Issue 2, 2015, Pages

  Moriwaki, K ^a   Bertin, J ^b   Gough, P J ^b   Orlowski, G M ^a   Chan, F K M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE INHIBITOR; CATHEPSIN; DEATH RECEPTOR; DNA; DOXORUBICIN; ETOPOSIDE; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 1; RECEPTOR INTERACTING PROTEIN KINASE 3; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; CA 074 METHYL ESTER; DIPEPTIDE; N-PIP-PHENYLALANINE-HOMOPHENYLALANINE-VINYL SULFONE PHENYL; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, HUMAN; RIPK3 PROTEIN, HUMAN; VINYL DERIVATIVE;

ARTICLE; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DNA MODIFICATION; ENZYME ACTIVITY; EPIGENETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; NECROPTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; APOPTOSIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; IN VITRO STUDY; MCF-7 CELL LINE; METABOLISM; NECROSIS; TUMOR CELL LINE;

METAZOA;

APOPTOSIS; CATHEPSINS; CELL LINE, TUMOR; DIPEPTIDES; DOXORUBICIN; ETOPOSIDE; HCT116 CELLS; HT29 CELLS; HUMANS; IN VITRO TECHNIQUES; MCF-7 CELLS; NECROSIS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA; VINYL COMPOUNDS;

EID: 84927660982     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.16     Document Type: Article

References (65)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012; 38: 589-598.
3. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
4. Moriwaki K, Chan FK. RIP3: a molecular switch for necrosis and inflammation. Genes Dev 2013; 27: 1640-1649.
5. Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao YS et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012; 150: 339-350.
6. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227.
7. Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014; 7: 971-981.
8. Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014; 54: 133-146.
9. Chen X, Li W, Ren J, Huang D, He WT, Song Y et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 2014; 24: 105-121.
10. Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 2014; 16: 55-65.
11. Walczak H. TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol Rev 2011; 244: 9-28.
12. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
13. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalphadependent apoptosis. Cell 2007; 131: 669-681.
14. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
15. Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One 2013; 8: e76841.
16. Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem 2003; 278: 51613-51621.
17. Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 1999; 13: 2514-2526.
18. Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N et al. Cleavage of RIP3 inactivates its caspaseindependent apoptosis pathway by removal of kinase domain. Cell Signal 2007; 19: 2056-2067.
19. Zhang H, Zhou X, McQuade T, Li J, Chan FK, Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011; 471: 373-376.
20. Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011; 471: 368-372.
21. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367.
22. Upton JW, Chan FK. Staying alive: cell death in antiviral immunity. Mol Cell 2014; 54: 273-280.
23. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
24. Fukasawa M, Kimura M, Morita S, Matsubara K, Yamanaka S, Endo C et al. Microarray analysis of promoter methylation in lung cancers. J Hum Genet 2006; 51: 368-374.
25. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STATbinding site in the p21WAF1 promoter region. Cancer Res 2000; 60: 3290-3298.
26. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6796.
27. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
28. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006; 11: 342-357.
29. Mandal P, Berger SB, Pillay S, Moriwaki K, Huang C, Guo H et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell 2014; 56: 481-495.
30. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C,Wallberg F et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448.
31. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ 2011; 18: 1376-1386.
32. Christofferson DE, Li Y, Hitomi J, Zhou W, Upperman C, Zhu H et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis 2012; 3: e320.
33. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
34. Silke J, Vucic D. IAP family of cell death and signaling regulators. Methods Enzymol 2014; 545: 35-65.
35. Loder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012; 26: 1020-1029.
36. Moriwaki K, Balaji S, McQuade TM, Malhotra N, Kang J, Chan FKM. The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair. Immunity 2014; 41: 567-578.
37. Moriwaki K, Chan FK. Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev 2014; 25: 167-174.
38. Lu C, Zhou LY, Xu HJ, Chen XY, Tong ZS, Liu XD et al. RIP3 overexpression sensitizes human breast cancer cells to parthenolide in vitro via intracellular ROS accumulation. Acta Pharmacol Sinica 2014; 35: 929-936.
39. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15: 135-147.
40. Schrader K, Huai J, Jockel L, Oberle C, Borner C. Non-caspase proteases: triggers or amplifiers of apoptosis? Cell Mol Life Sci 2010; 67: 1607-1618.
41. Nugues AL, El Bouazzati H, Hetuin D, Berthon C, Loyens A, Bertrand E et al. RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspasemediated p65/RelA cleavage. Cell Death Dis 2014; 5: e1384.
42. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443-453.
43. Colbert LE, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW et al. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Cancer 2013; 119: 3148-3155.
44. Wang Q, Chen W, Xu X, Li B, He W, Padilla MT et al. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis 2013; 34: 2119-2128.
45. Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res 2009; 69: 2809-2816.
46. Chan FK, Luz NF, Moriwaki K. Programmed necrosis in the cross talk of cell death and inflammation. Annu Rev Immunol 2014; e-pub ahead of print 10 December 2014.
47. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2014; 6: 1062-1074.
48. Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD et al. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med 2014; 20: 204-208.
49. Chromik J, Safferthal C, Serve H, Fulda S. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 2014; 344: 101-109.
50. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S et al. Smac mimetic bypasses apoptosis resistance in FADD-or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011; 13: 971-979.
51. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013; 4: e802.
52. Voigt S, Philipp S, Davarnia P, Winoto-Morbach S, Roder C, Arenz C et al. TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. BMC Cancer 2014; 14: 74.
53. Basit F, Cristofanon S, Fulda S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ 2013; 20: 1161-1173.
54. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010; 120: 1310-1323.
55. Fulda S. Therapeutic exploitation of necroptosis for cancer therapy. Semin Cell Dev Biol 2014; 35: 51-56.
56. Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M et al. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia 2014; 28: 1861-1871.
57. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6: 1641-1649.
58. Fu Z, Deng B, Liao Y, Shan L, Yin F, Wang Z et al. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 2013; 13: 580.
59. Cho Y, McQuade T, Zhang HB, Zhang JK, Chan FKM. RIP1-dependent and independent effects of necrostatin-1 in necrosis and t cell activation. PLoS One 2011; 6: e23209.
60. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
61. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012; 72: 3499-3511.
62. Tu HC, Ren D, Wang GX, Chen DY, Westergard TD, Kim H et al. The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc Natl Acad Sci USA 2009; 106: 1093-1098.
63. Paquet C, Sane AT, Beauchemin M, Bertrand R. Caspase-and mitochondrial dysfunctiondependent mechanisms of lysosomal leakage and cathepsin B activation in DNA damage-induced apoptosis. Leukemia 2005; 19: 784-791.
64. Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE. Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. Mol Cancer Ther 2005; 4: 733-742.
65. Aits S, Jaattela M. Lysosomal cell death at a glance. J Cell Sci 2013; 126: 1905-1912.